Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Phase 2, Dose Finding Study to Evaluate the Efficacy and Safety of LIB003 in Patients on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Lerodalcibep (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Therapeutic Use
- 14 Feb 2019 Status changed from active, no longer recruiting to completed.
- 01 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 15 Jun 2018 New trial record